Literature DB >> 11862988

Melatonin reverses neurochemical alterations induced by 6-OHDA in rat striatum.

L M V Aguiar1, S M M Vasconcelos, F C F Sousa, G S B Viana.   

Abstract

The present work showed that the intrastriatal injection of 6-OHDA significantly decreases DA, DOPAC and HVA levels in that rat brain structure. Although there is also a decrease in 5-HT levels no changes were observed in 5-HIAA levels as compared to controls. On the other hand, melatonin (2, 5, 10 and 25 mg/kg. i.p., daily for 7 days) treatment starting 1 h after 6-OHDA lesions, partially reverses the decreases caused by 6-OHDA lesions on these neurotransmitter levels, and contents were brought to approximately 50% of that observed in the contralateral sides of controls or of melatonin treated group. Melatonin was more efficient at the doses of 5 and 10 mg/kg, i.p., and effects were similar between the lowest and highest doses characteristic of a bell-shaped type of response. The apomorphine-induced rotational behavior (3 mg/kg, i.p.) was blocked by 60, 89, 78 and 47% after the doses of 2, 5, 10 and 25 mg/kg, i.p., respectively. Similarly, in this case the doses of 5 and 10 mg/kg were also more efficient. Melatonin (5 mg/kg) produced an upregulation of D1 receptors associated with a decrease in Kd value. While no change was observed in maximum density of D2 receptors, the Kd value was also decreased.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862988     DOI: 10.1016/s0024-3205(01)01480-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Beneficial Effect of Melatonin on Motor and Memory Disturbances in 6-OHDA-Lesioned Rats.

Authors:  Lyubka Tancheva; Maria Lazarova; Luciano Saso; Reni Kalfin; Miroslava Stefanova; Diamara Uzunova; Atanas G Atanasov
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

Review 2.  Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?

Authors:  Naveen Kumar Singhal; Garima Srivastava; Sonal Agrawal; Swatantra Kumar Jain; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2011-12-24       Impact factor: 5.590

3.  Neurotoxins: free radical mechanisms and melatonin protection.

Authors:  Russel J Reiter; Lucien C Manchester; Dun-Xian Tan
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

4.  Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis.

Authors:  Ana Luisa Gutierrez-Valdez; Verónica Anaya-Martínez; José Luis Ordoñez-Librado; Ricardo García-Ruiz; Carmen Torres-Esquivel; Montserrat Moreno-Rivera; Javier Sánchez-Betancourt; Enrique Montiel-Flores; Maria Rosa Avila-Costa
Journal:  ISRN Neurol       Date:  2012-02-01

Review 5.  Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease.

Authors:  Santiago Pérez-Lloret; Daniel P Cardinali
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

6.  Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease.

Authors:  Pablo Duarte; Patrycja Michalska; Enrique Crisman; Antonio Cuadrado; Rafael León
Journal:  Antioxidants (Basel)       Date:  2022-01-27

Review 7.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.